These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 36288537)

  • 1. 177Lu-PSMA Therapy for Metastatic Castration-Resistant Prostate Cancer: A Mini-Review of State-of-the-Art.
    AlSadi R; Bouhali O; Dewji S; Djekidel M
    Oncologist; 2022 Dec; 27(12):e957-e966. PubMed ID: 36288537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term outcome of 177Lu-PSMA-617 radioligand therapy in heavily pre-treated metastatic castration-resistant prostate cancer patients.
    Yadav MP; Ballal S; Sahoo RK; Tripathi M; Damle NA; Shamim SA; Kumar R; Seth A; Bal C
    PLoS One; 2021; 16(5):e0251375. PubMed ID: 33970962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 177 Lu-PSMA-617 radioligand therapy of metastatic castration-resistant prostate cancer: Initial 254-patient results from a prospective registry (REALITY Study).
    Khreish F; Ghazal Z; Marlowe RJ; Rosar F; Sabet A; Maus S; Linxweiler J; Bartholomä M; Ezziddin S
    Eur J Nucl Med Mol Imaging; 2022 Feb; 49(3):1075-1085. PubMed ID: 34494131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic factors of overall and prostate-specific antigen-progression-free survival in metastatic castration-resistant prostate cancer patients treated with
    Telli T; Tuncel M; Karabulut E; Aksoy S; Erman M; Akdogan B; Caglar M
    Prostate; 2023 Jun; 83(8):792-800. PubMed ID: 36919876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response and outcome of liver metastases in patients with metastatic castration-resistant prostate cancer (mCRPC) undergoing
    Khreish F; Kochems N; Rosar F; Sabet A; Ries M; Maus S; Saar M; Bartholomä M; Ezziddin S
    Eur J Nucl Med Mol Imaging; 2021 Jan; 48(1):103-112. PubMed ID: 32378019
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Single-Arm, Low-Dose, Prospective Study of
    Wang G; Zang J; Jiang Y; Liu Q; Sui H; Wang R; Fan X; Zhang J; Zhu Z; Chen X
    J Nucl Med; 2023 Apr; 64(4):611-617. PubMed ID: 36328486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Activity and Adverse Events of Actinium-225-PSMA-617 in Advanced Metastatic Castration-resistant Prostate Cancer After Failure of Lutetium-177-PSMA.
    Feuerecker B; Tauber R; Knorr K; Heck M; Beheshti A; Seidl C; Bruchertseifer F; Pickhard A; Gafita A; Kratochwil C; Retz M; Gschwend JE; Weber WA; D'Alessandria C; Morgenstern A; Eiber M
    Eur Urol; 2021 Mar; 79(3):343-350. PubMed ID: 33293081
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Third-line treatment and
    von Eyben FE; Roviello G; Kiljunen T; Uprimny C; Virgolini I; Kairemo K; Joensuu T
    Eur J Nucl Med Mol Imaging; 2018 Mar; 45(3):496-508. PubMed ID: 29247284
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extended therapy with [
    Mader N; Nguyen Ngoc C; Kirkgöze B; Baumgarten J; Groener D; Klimek K; Happel C; Tselis N; Chun FKH; Grünwald F; Sabet A
    Eur J Nucl Med Mol Imaging; 2023 May; 50(6):1811-1821. PubMed ID: 36702927
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment Outcome, Toxicity, and Predictive Factors for Radioligand Therapy with
    Heck MM; Tauber R; Schwaiger S; Retz M; D'Alessandria C; Maurer T; Gafita A; Wester HJ; Gschwend JE; Weber WA; Schwaiger M; Knorr K; Eiber M
    Eur Urol; 2019 Jun; 75(6):920-926. PubMed ID: 30473431
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Update on radioligand therapy with
    Fuoco V; Argiroffi G; Mazzaglia S; Lorenzoni A; Guadalupi V; Franza A; Scalorbi F; Aliberti G; Chiesa C; Procopio G; Seregni E; Maccauro M
    Tumori; 2022 Aug; 108(4):315-325. PubMed ID: 34405748
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular analysis of circulating tumor cells of metastatic castration-resistant Prostate Cancer Patients receiving
    Kessel K; Seifert R; Weckesser M; Roll W; Humberg V; Schlack K; Bögemann M; Bernemann C; Rahbar K
    Theranostics; 2020; 10(17):7645-7655. PubMed ID: 32685010
    [No Abstract]   [Full Text] [Related]  

  • 13. Explorative analysis of a score predicting the therapy response of patients with metastatic, castration resistant prostate cancer undergoing radioligand therapy with
    Huang K; Schatka I; Rogasch JMM; Lindquist RL; De Santis M; Erber B; Radojewski P; Brenner W; Amthauer H
    Ann Nucl Med; 2021 Mar; 35(3):314-320. PubMed ID: 33351172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of
    Yadav MP; Ballal S; Sahoo RK; Tripathi M; Seth A; Bal C
    Theranostics; 2020; 10(20):9364-9377. PubMed ID: 32802197
    [No Abstract]   [Full Text] [Related]  

  • 15. Factors predicting biochemical response and survival benefits following radioligand therapy with [
    Manafi-Farid R; Harsini S; Saidi B; Ahmadzadehfar H; Herrmann K; Briganti A; Walz J; Beheshti M
    Eur J Nucl Med Mol Imaging; 2021 Nov; 48(12):4028-4041. PubMed ID: 33677734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radioligand Therapy With
    Yadav MP; Ballal S; Sahoo RK; Dwivedi SN; Bal C
    AJR Am J Roentgenol; 2019 Aug; 213(2):275-285. PubMed ID: 30995089
    [No Abstract]   [Full Text] [Related]  

  • 17. Prediction of response and survival after standardized treatment with 7400 MBq
    Rasul S; Hartenbach M; Wollenweber T; Kretschmer-Chott E; Grubmüller B; Kramer G; Shariat S; Wadsak W; Mitterhauser M; Pichler V; Vraka C; Hacker M; Haug AR
    Eur J Nucl Med Mol Imaging; 2021 May; 48(5):1650-1657. PubMed ID: 33128131
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Genomic characterization of metastatic castration-resistant prostate cancer patients undergoing PSMA radioligand therapy: A single-center experience.
    Satapathy S; Das CK; Aggarwal P; Sood A; Parihar AS; Singh SK; Mittal BR
    Prostate; 2023 Feb; 83(2):169-178. PubMed ID: 36259290
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 177Lu-Labeled Prostate-Specific Membrane Antigen Radioligand Therapy of Metastatic Castration-Resistant Prostate Cancer: Safety and Efficacy.
    Baum RP; Kulkarni HR; Schuchardt C; Singh A; Wirtz M; Wiessalla S; Schottelius M; Mueller D; Klette I; Wester HJ
    J Nucl Med; 2016 Jul; 57(7):1006-13. PubMed ID: 26795286
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    Cao J; Chen Y; Hu M; Zhang W
    Ann Nucl Med; 2021 Aug; 35(8):861-870. PubMed ID: 34176105
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.